Home » Stocks » Applied Genetic Technologies

Applied Genetic Technologies Corporation (AGTC)

Stock Price: $5.52 USD 0.17 (3.18%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 142.23M
Revenue (ttm) 2.86M
Net Income (ttm) -41.90M
Shares Out 25.77M
EPS (ttm) -2.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $5.52
Previous Close $5.35
Change ($) 0.17
Change (%) 3.18%
Day's Open 5.28
Day's Range 5.28 - 5.59
Day's Volume 301,181
52-Week Range 2.29 - 10.42

More Stats

Market Cap 142.23M
Enterprise Value 63.19M
Earnings Date (est) Sep 14, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.77M
Float 19.89M
EPS (basic) -2.19
EPS (diluted) -2.18
FCF / Share -1.63
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.95M
Short Ratio 4.74
Short % of Float 10.86%
Beta 2.60
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 49.75
PB Ratio 1.60
Revenue 2.86M
Operating Income -43.80M
Net Income -41.90M
Free Cash Flow -36.29M
Net Cash 79.04M
Net Cash / Share 3.07
Gross Margin 974.61%
Operating Margin -1,532.07%
Profit Margin -1,465.70%
FCF Margin -1,269.15%
ROA -26.58%
ROE -48.41%
ROIC -79.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(173.01% upside)
Current: $5.52
Target: 15.07
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth72.38%-38.73%-16.66%1911.94%108.5%19.85%-12.94%-
Gross Profit41.6924.1939.4747.362.351.130.941.08
Operating Income-4.35-22.381.90-2.09-24.53-12.56-3.59-2.06
Net Income-2.01-21.300.41-1.38-24.32-15.91-4.99-1.92
Shares Outstanding18.1618.1118.0717.8116.253.570.110.11
Earnings Per Share-0.11-1.180.02-0.08-1.50-4.46-45.78-17.65
Operating Cash Flow-23.46-32.52-31.0070.99-19.49-11.93-2.78-1.37
Capital Expenditures-0.16-0.66-0.74-2.47-0.23-0.16-0.35-0.01
Free Cash Flow-23.62-33.18-31.7468.52-19.71-12.09-3.13-1.38
Cash & Equivalents82.0010512798.5361.6473.0722.890.82
Total Debt-------1.02
Net Cash / Debt82.0010512798.5361.6473.0722.89-0.20
Book Value78.7199.1811510985.5374.87-36.18-31.29
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Applied Genetic Technologies Corporation
Country United States
Employees 85
CEO Susan B. Washer

Stock Information

Ticker Symbol AGTC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AGTC
IPO Date March 27, 2014


Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. The company also has initiated one preclinical program in otology and three preclinical programs in targeting central nervous system disorders, including one in adrenoleukodystrophy. Applied Genetic Technologies Corporation has collaboration agreements with Synpromics Limited and University of Florida; Bionic Sight, LLC; and Otonomy, Inc. The company was founded in 1999 and is headquartered in Alachua, Florida.